![[Free Webinar] Guide to Securing Your Entire Identity Lifecycle Against AI-Powered Threats](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqbZf4bsDp6ei3fmQ8swm7GB5XoRrhZSFE7ZNhRLFO49KlmdgpIDCZWMSv7rydpEShIrNb9crnH5p6mFZbURzO5HC9I4RlzJazBBw5aHOTmI38sqiZIWPldRqut4bTgegipjOk5VgktVOwCKF_ncLeBX-pMTO_GMVMfbzZbf8eAj21V04y_NiOaSApGkM/s1600/webinar-play.jpg?#)
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY). It is the most valuable healthcare company in the world, with a market cap of around $800 billion. And yet it may still not be too late to invest in it.The company's dominance in the GLP-1 drug market makes it a promising long-term investment to hang on to. Last year, its sales rose by 32%, but there could be even more growth on the horizon.Pharmaceutical giant Eli Lilly has been experiencing a surge in revenue growth lately due to the massive popularity of its two GLP-1 drugs, Zepbound and Mounjaro. The former is approved for weight loss and the latter for diabetes. They can help patients shed significant pounds and transform their lives for the better. Demand has been through the roof, and they generated a combined $16.5 billion in sales last year. Continue reading
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY). It is the most valuable healthcare company in the world, with a market cap of around $800 billion. And yet it may still not be too late to invest in it.
The company's dominance in the GLP-1 drug market makes it a promising long-term investment to hang on to. Last year, its sales rose by 32%, but there could be even more growth on the horizon.
Pharmaceutical giant Eli Lilly has been experiencing a surge in revenue growth lately due to the massive popularity of its two GLP-1 drugs, Zepbound and Mounjaro. The former is approved for weight loss and the latter for diabetes. They can help patients shed significant pounds and transform their lives for the better. Demand has been through the roof, and they generated a combined $16.5 billion in sales last year.
